Northwest Biotherapeutics Sets 2024 Annual Meeting for June 29

Ticker: NWBO · Form: DEF 14A · Filed: 2024-06-03T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, annual-meeting, shareholder-vote

Related Tickers: NWBO

TL;DR

NWBO annual meeting June 29th - vote ahead of time!

AI Summary

Northwest Biotherapeutics, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 29, 2024, at 1:30 p.m. local time. The meeting will take place at the offices of Gibson, Dunn & Crutcher LLP in Washington, DC, and will also be accessible remotely via an audio-only link. Stockholders are encouraged to vote prior to the meeting as remote access will not permit voting.

Why It Matters

This annual meeting is a crucial event for shareholders to vote on company matters and hear updates directly from management.

Risk Assessment

Risk Level: medium — DEF 14A filings often precede significant corporate events or shareholder votes, which can introduce volatility.

Key Players & Entities

FAQ

When is the 2024 Annual Meeting of Stockholders for Northwest Biotherapeutics, Inc.?

The 2024 Annual Meeting of Stockholders is scheduled for Saturday, June 29, 2024, at 1:30 p.m. local time.

Where will the Annual Meeting be held?

The meeting will be held at the offices of Gibson, Dunn & Crutcher LLP, 1050 Connecticut Avenue NW, Washington, DC 20036, and can also be accessed remotely via an audio-only link.

Can stockholders vote remotely during the meeting?

No, stockholders who cannot attend in person will need to vote prior to the meeting as the audio-only link will not enable voting during the meeting.

What type of filing is this document?

This document is a Definitive Proxy Statement (DEF 14A) filed with the Securities and Exchange Commission.

What is the purpose of this filing?

This filing serves as the Proxy Statement and Notice of the Annual Meeting of Stockholders for Northwest Biotherapeutics, Inc.

Filing Stats: 4,839 words · 19 min read · ~16 pages · Grade level 11.4 · Accepted 2024-06-03 17:22:55

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 24 CORPORATE GOVERNANCE MATTERS 26

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 PRINCIPAL ACCOUNTANT FEES AND SERVICES 46 OTHER MATTERS 47 ADDITIONAL INFORMATION 48 APPENDIX A A-1 APPENDIX B B-1 i TABLE OF CONTENTS NORTHWEST BIOTHERAPEUTICS, INC. 4800 Montgomery Lane Suite 800 Bethesda, Maryland 20814 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 29, 2024 This proxy statement is being furnished in connection with the solicitation of proxies by the Board of Directors of Northwest Biotherapeutics, Inc. ("we," "us," "our" or the "Company") for use at the Annual Meeting of Stockholders (the "Annual Meeting"), to be held on Saturday, June 29, 2024 at 1:30 p.m. Eastern Time, and any adjournments or postponements of the Annual Meeting. The Board of Directors, or the "Board," is soliciting proxies for the purposes set forth in the accompanying Notice of the Annual Meeting of Stockholders. Record Date and Share Ownership Only stockholders of record on our books at the close of business on May 9, 2024 will be entitled to attend and vote at the Annual Meeting and any adjournments or postponements of the Annual Meeting. As of the close of business on May 9, 2024, we had 1,210,879,427 shares of common stock outstanding and 1,211,971 shares of preferred stock outstanding. Each share of common stock entitles the record holder to one vote on each matter to be voted upon at the Annual Meeting. Each share of preferred stock is convertible into 25 shares of common stock and hence entitles the record holder to 25 votes on each matter to be voted upon at the Annual Meeting. Copies of the Notice of the Annual Meeting of Stockholders, this proxy statement, the enclosed proxy card and the 2023 Annual Report are expected to be mailed to stockholders of record on or about June 3, 2024. Exhibits to the 2023 Annual Report will be provided to any stockholder at no charge upon written or oral request to our corporate secretary at the address set forth under " Communication with

View on Read The Filing